GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Canopy Growth Corp (NAS:CGC) » Definitions » EBITDA Margin %

Canopy Growth (Canopy Growth) EBITDA Margin %

: -247.74% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Canopy Growth's EBITDA for the three months ended in Dec. 2023 was $-145.0 Mil. Canopy Growth's Revenue for the three months ended in Dec. 2023 was $58.5 Mil. Therefore, Canopy Growth's EBITDA margin for the quarter that ended in Dec. 2023 was -247.74%.


Canopy Growth EBITDA Margin % Historical Data

The historical data trend for Canopy Growth's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canopy Growth Annual Data
Trend Jul13 Dec14 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -283.90 -345.39 -283.25 -23.74 -770.32

Canopy Growth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -206.94 -560.77 10.04 -139.18 -247.74

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canopy Growth EBITDA Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Canopy Growth's EBITDA Margin % falls into.



Canopy Growth EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Canopy Growth's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-2268.247/294.456
=-770.32 %

Canopy Growth's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-144.969/58.516
=-247.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Canopy Growth  (NAS:CGC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Canopy Growth EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Canopy Growth's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Canopy Growth (Canopy Growth) Business Description

Traded in Other Exchanges
Address
1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include sports drink BioSteel, skincare products under This Works, Martha Stewart CBD, and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Executives
Theresa Yanofsky director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
David Angelo Lazzarato director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Judy Schmeling director C/O HSN, INC., 1 HSN DRIVE, ST.PETERSBURG FL 33729
Hong Judy Eun Joo officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS Z4 K7A 0A8
David Eric Klein director, officer: Chief Executive Officer 207 HIGH POINT DRIVE, VICTOR NY 14564
Thomas Carlton Stewart officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Christelle Gedeon officer: See Remarks 3 HOLLYHOCK COURT, TORONTO Z4 M3B 0B4
Garth Hankinson director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Greenstar Ii Holdings Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Greenstar Ii Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Rade Nikola Kovacevic officer: President 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Phillip Stephen Shaer officer: Chief Legal Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Grant Julious C. Jr officer: Chief Commercial Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Sabia James A. Jr. director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Tomas Iv Shipley officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8